# Aclaris Therapeutics share price today (Aclaris Therapeutics, Inc., ACRS)

> Aclaris Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ACRS · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/acrs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.68 (+58.6% in a year)
- Revenue (Jun 2026): $1.6 M (−8.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −$21.5 M (one-off item, see below)
- ROE: −63%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Aclaris Therapeutics share price today? Aclaris Therapeutics, Inc.'s share price was $3.68 at the close on 4 November 2026. It has been moving sideways for 6 weeks. That is 18.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $6, and at that close it sat 33% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 10 years the share price moved −82% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Aclaris Therapeutics pay? Aclaris Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Aclaris Therapeutics on? Aclaris Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Aclaris Therapeutics profitable? Aclaris Therapeutics, Inc. posted a net loss of $21.5 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $64.9 M. That loss is 1,320.1% of the quarter's revenue. The same quarter a year earlier lost $15.4 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$21.5 M it is bigger than the quarter's whole revenue of $1.6 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,469.5% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Aclaris Therapeutics make, and is it growing? Aclaris Therapeutics, Inc. reported $1.6 M of revenue in the Jun 2026 quarter, −8.3% on the same quarter a year earlier. Over 4 years it has grown 3.7% a year on average. The last full year, FY25, came in at $7.8 M. The last four reported quarters add to $8.2 M. FY25 revenue was $7.8 M, −58.2% on the year before. Recent pace: the last four quarters grew −20.3% on average, against 3.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −51.0%, against −49.3% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Aclaris Therapeutics keep? Aclaris Therapeutics, Inc.'s sales have fallen to very little: FY25 revenue was $7.8 M, against $31.2 M in FY23. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Aclaris Therapeutics' profit turning into cash? Aclaris Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $47.1 M of cash, against −$64.9 M of profit. After $111 K of spending on assets, free cash was −$47.2 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Aclaris Therapeutics' cash go? Aclaris Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.5 M on assets over the last 3 years. Averaged over those years that is 6.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.5 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Aclaris Therapeutics' P/E ratio, and how does it compare with its own history? Aclaris Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Aclaris Therapeutics, Inc. at 72.9× its FY25 revenue of $7.8 M. The P/E comes back here once profit turns positive. ## Is the Aclaris Therapeutics business getting better or worse? Aclaris Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Aclaris Therapeutics earn on its capital? Aclaris Therapeutics, Inc. earned a ROE of −63% in FY25. That is up from a low of −85% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −41%, a number that says nothing useful about the business. ## Does Aclaris Therapeutics have too much debt? Aclaris Therapeutics, Inc. has total debt of $1.9 M against shareholder equity of $125 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Aclaris Therapeutics shareholding pattern? 13.8% of Aclaris Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 3.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Aclaris Therapeutics from balance-sheet trouble? For Aclaris Therapeutics, Inc., the Z-score is −4.91. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −4.91 is inside the danger zone, so the balance sheet is a real risk. ## How does Aclaris Therapeutics rank in its industry? There is no score against its industry: Aclaris Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Aclaris Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Aclaris Therapeutics in size? Aclaris Therapeutics is the 135th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: SL Science Holding, DBV Technologies S.A. and Crescent Biopharma, Inc. Just below it: Surrozen, Inc., Puma Biotechnology, Inc. and Valneva SE. ### Biotechnology companies close in size

1. [SL Science Holding Limited](https://www.sectoralpha.in/us/stocks/slbt) $633 million
2. [DBV Technologies S.A.](https://www.sectoralpha.in/us/stocks/dbvt) $622 million
3. [Crescent Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/cbio) $592 million
4. Aclaris Therapeutics, Inc. $570 million
5. [Surrozen, Inc.](https://www.sectoralpha.in/us/stocks/srzn) $554 million
6. [Puma Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/pbyi) $552 million
7. [Valneva SE](https://www.sectoralpha.in/us/stocks/valn) $539 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Rezolve AI PLC](https://www.sectoralpha.in/us/stocks/rzlv) $571 million · Software - Infrastructure
2. [American Integrity Insurance Group, Inc.](https://www.sectoralpha.in/us/stocks/aii) $571 million · Insurance - Property & Casualty
3. Aclaris Therapeutics, Inc. $570 million
4. [Bankwell Financial Group, Inc.](https://www.sectoralpha.in/us/stocks/bwfg) $569 million · Banks - Regional
5. [EVgo, Inc.](https://www.sectoralpha.in/us/stocks/evgo) $569 million · Specialty Retail

## What else do people ask about Aclaris Therapeutics? ### What were Aclaris Therapeutics's latest quarterly results? Aclaris Therapeutics, Inc. reported revenue of $1.6 M and a net loss of $21.5 M for the Jun 2026 quarter. Earnings per share were −$0.15. The operating margin was −1,469.5%, 518.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Aclaris Therapeutics's market cap? Aclaris Therapeutics, Inc.'s market capitalisation is $570 M at a stock price of $3.68. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Aclaris Therapeutics performing? Aclaris Therapeutics, Inc.'s share price has been moving sideways for 6 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Aclaris Therapeutics's stock price go up? This page does not forecast Aclaris Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $3.68, and it has been moving sideways for 6 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Aclaris Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Aclaris Therapeutics a stock worth studying right now? What the numbers show: Aclaris Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.